The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
Advised 3i Infrastructure plc on the sale of Wireless Infrastructure Group Limited, a leading independent telecommunications infrastructure provider focusing on mobile towers and indoor connectivity
Advised Alimentation Couche-Tard Inc., a multinational convenience store operator, on the strategic review and subsequent sale of its controlling ownership (which included 100% of the general partner interest, 100% of the incentive distribution rights and ~7.5mm limited partner units) in CrossAmerica Partners LP (NYSE: CAPL), a leading wholesale fuels distributor and convenience store lessor in the United States
Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas
Advised the Government of Canada on the acquisition of the Trans Mountain Pipeline system, the Trans Mountain Expansion Project and related pipeline and terminal assets from Kinder Morgan Canada Limited
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Capital Power Income L.P., a Canadian power trust with a portfolio of 20 power generation assets located in Canada and the United States (total net generating capacity of 1,400 MW), on its sale to Atlantic Power Corporation
Advised Chilton Investment Company on Trident’s financial restructuring and emergence from CCAA / Chapter 11 bankruptcy protection including the negotiation of a new equity investment
Advised the Independent Committee of the Board of Directors of EPCOR Power L.P., an Alberta-based power trust, on approval of the transfer of its GP interest and 30.6% LP interest from EPCOR Utilities to a newly formed company, Capital Power Corporation
Advised TransAlta Corporation, a power generation and wholesale marketing company, on an unsolicited offer from LS Power Equity Partners / Global Infrastructure Partners